Could liquid cartilage help you avoid bigger surgery

Avoiding “the next step” — an ankle fusion, a knee replacement, or an early hip replacement — usually comes down to one practical question: is the problem a localised cartilage defect that can be supported to heal, or is it widespread arthritis where the joint surface is broadly worn.

Liquid Cartilage™ (often referring to ChondroFiller Liquid) sits in the joint-preservation end of that spectrum: it is mainly discussed for symptomatic, focal, full‑thickness cartilage lesions in an otherwise reasonably preserved joint, rather than for established, diffuse osteoarthritis. In the hip arthroscopy literature, for example, ChondroFiller Liquid is presented as a one‑step way to fill discrete full‑thickness defects encountered alongside femoroacetabular impingement, where microfracture has been the standard for smaller lesions but may produce fibrocartilage with variable durability beyond 2–3 years. NHS guidance, by contrast, frames hip replacement around severe pain and disability that persists despite conservative options and significantly affects mobility and quality of life.

In current clinical use as an injection-led pathway, Liquid Cartilage is best understood as an image‑guided outpatient injectable collagen scaffold — not a drug, not a stem‑cell transplant, and not “keyhole surgery” in itself. ChondroFiller Liquid is described as a cell‑free, native type I collagen hydrogel supplied in a two‑chamber syringe; it mixes during delivery and forms a resorbable gel scaffold over minutes, aiming to provide a framework that supports the body’s own repair response. Independent educational material also stresses it is not a “miracle gel” and does not regrow normal hyaline cartilage across established osteoarthritis.

A useful way to place it in the wider decision pathway is:

• Symptom management (activity modification, physiotherapy, analgesia)
• Biologic / injection support (where an injectable scaffold may fit for selected focal defects)
• Surgical cartilage restoration (microfracture, scaffold‑augmented techniques, MACI/ACI, osteochondral grafts)
• Joint replacement (hip/knee) or fusion (ankle) for advanced, diffuse damage

Evidence that most directly supports durable joint preservation still comes from established procedures — for example, microfracture outperforming debridement in osteochondral talar lesions, and 5‑year results in talar MACI series — and from long‑term knee MACI reviews. For injectable and other cell‑free scaffolds, knee randomised evidence shows mixed short‑term findings at 12–24 months overall, although at least one off‑the‑shelf scaffold has shown superior 2‑year outcomes versus debridement/microfracture. What is not yet shown in joint‑specific trials is that Liquid Cartilage injections reliably prevent later fusion or replacement; the more defensible aim is supporting symptoms and function in carefully defined focal defects while keeping bigger surgery on the table if the joint progresses.

Liquid cartilage for ankle lesions and fusion risk

An osteochondral lesion of the talus (OLT) is a common “focal damage” pattern in the ankle after a sprain or impact injury, where a small area of cartilage (sometimes with underlying bone) is disrupted on the top of the talus. In practice this can present as deep ankle pain, swelling after activity, and mechanical symptoms such as catching or giving way — often in younger, active adults rather than in older people with established, widespread ankle arthritis.

For many symptomatic OLTs, the baseline surgical benchmark has been arthroscopic debridement with or without microfracture. In a retrospective comparison published in Frontiers in Surgery (debridement, n=39; microfracture, n=42), both groups improved after surgery, but the microfracture group had significantly larger gains in AOFAS ankle scores and pain VAS than debridement alone; the most favourable results were reported in younger (≤30 years) and lower‑BMI male patients. That pattern supports microfracture as more than “tidying up” for selected focal talar lesions, while also hinting that patient factors (age and body weight in particular) can meaningfully influence outcomes.

When the talar defect is deeper, more complex, or has already failed a simpler repair, cell-based matrix techniques have the strongest published ankle-specific results. A prospective MACI series in 22 patients (mean age 23.9 years; mean lesion size 1.94 cm²) reported large improvements that were maintained at around 63.5 months: mean AOFAS scores rose from 70.1 preoperatively to about 95, pain VAS fell from 5.7 to 0.9, and MRI MOCART scores improved into the mid‑80s by final follow‑up. Importantly, the authors described most clinical improvement occurring within the first 12 months and then remaining stable through the 5‑year mark — a useful “durability” signal for joint-preservation planning in the talus.

Against that backdrop, “Liquid Cartilage” approaches are easiest to understand as a scaffold-based attempt to support repair in a focal talar defect without committing to a two‑stage, cell-expansion pathway. Conceptually, an image‑guided injectable collagen scaffold aims to fill and stabilise the defect and provide a temporary matrix that may encourage the body’s own cells to populate the area, rather than simply smoothing the surface as in debridement. This sits closer to the logic of matrix-assisted repair than to pain-relief injections, but it is still intended for discrete lesions rather than for an ankle where the joint surface is broadly worn.

The key practical limitation in 2025 is that ankle-specific clinical evidence for injectable collagen gels marketed as “Liquid Cartilage” (including ChondroFiller-type products) remains thin compared with microfracture and talar MACI. Independent clinical education materials emphasise that ChondroFiller is not a “miracle gel”, does not regenerate normal hyaline cartilage across established osteoarthritis, and has limited published clinical evidence — which matters when trying to answer hard end points such as “fewer repeat arthroscopies” or “avoiding fusion”. In other words, the ankle discussion still leans heavily on what is known from established talar procedures (microfracture and MACI) plus the general rationale for scaffolds, rather than on talus-specific outcome series for the injection itself.

Ankle fusion (tibiotalar arthrodesis) is generally considered later in the pathway, when pain and loss of function are driven by advanced, often diffuse joint surface damage rather than by a single contained OLT. In that setting — where the ankle behaves more like end‑stage arthritis than an isolated defect — a focal scaffold treatment is unlikely to change the underlying mechanical reality that the joint surface is globally compromised.

Taken together, an injectable scaffold may be a reasonable joint-preservation bridge for carefully selected focal talar lesions, particularly when the goal is to support function and postpone more invasive surgery. What cannot currently be claimed from the published ankle literature is that it reliably reduces the need for repeat arthroscopy versus microfracture, or meaningfully changes the long-term probability of ankle fusion compared with established reconstructive options such as talar MACI.

Knee defects moving beyond microfracture alone

Knee cartilage repair most often comes up in active adults in their 20s–50s who have a contained, symptomatic defect on the femoral condyle or trochlea—often in the 1–7 cm² range—rather than established, widespread tricompartmental osteoarthritis. The day‑to‑day problem is usually swelling after sport, sharp pain on stairs or squatting, and occasional catching or locking, with an MRI report describing a focal full‑thickness lesion rather than “bone‑on‑bone” change.

Microfracture became popular because it is a single keyhole operation and, for smaller defects, can deliver a short‑term improvement in pain and function. The principle is marrow stimulation: small perforations are made in the subchondral bone so marrow cells and growth factors can enter the defect and form a repair clot. The trade‑off—already flagged earlier in this article—is that the repair tissue is typically fibrocartilage rather than the organised hyaline cartilage found in a healthy joint surface, and concerns remain about durability and the effect on the subchondral bone plate.

The best summary of how microfracture is performing against “microfracture plus scaffold” in the modern knee literature comes from a 2024 systematic review and meta‑analysis of 10 randomised controlled trials (378 patients). When outcomes were pooled at 12 and 24 months, scaffold‑augmented approaches (often described as matrix‑induced chondrogenesis) did not show a statistically significant overall advantage over microfracture alone across commonly used measures—IKDC and KOOS function scores, pain VAS, and MRI‑based MOCART assessments. Importantly, the same review highlighted a recurring pattern in longer follow‑up: microfracture improvements can fade after the early period, and some individual longer‑term trials have favoured adding a scaffold, even if that signal is not consistent across all studies at 1–2 years.

One reason the field has moved beyond “microfracture only” is that there are scaffold technologies with randomised evidence of better early clinical outcomes than standard care. In a multicentre RCT involving 251 adults across 26 centres, a cell‑free, off‑the‑shelf aragonite‑based scaffold was compared with surgeon’s choice standard care (debridement or microfracture) for 1–7 cm² cartilage lesions. The earlier 2‑year analysis reported superior clinical outcomes in the scaffold arm than in the debridement/microfracture arm, and the subsequent 5‑year follow‑up has been framed around durability, treatment failure, and whether patients progress to bigger operations such as osteotomy or arthroplasty.

Where does “Liquid Cartilage” fit beside these scaffold‑augmented procedures? Mechanistically, it sits in the same broad family: a cell‑free scaffold placed into a focal defect with the intent of stabilising the lesion, providing a temporary 3‑D structure, and supporting the body’s own cells to populate the area. Liquid Cartilage educational materials describe these gels as extracellular‑matrix‑mimicking hydrogels (collagen‑based or synthetic) that fill defects rather than simply lubricating the joint in the way hyaluronic acid injections are often discussed.

The injectable aspect matters mainly for delivery and conformity rather than for proving a fundamentally different biology. In preclinical work on injectable sol–gel scaffolds (for example PLGA‑based systems), the material can be injected to fill an irregular defect, then harden in situ into a porous structure that allows fluid penetration and cell ingrowth; in animal models, fibrocartilage‑like repair tissue has been reported by about 6 months. That kind of evidence supports plausibility for injectable scaffolds as “defect fillers”, but it is not the same as showing that a specific injectable collagen gel reliably outperforms microfracture in a human knee at 5 years.

A practical way to interpret the mixed picture from 2013–2024 trial data is:

• At 12–24 months, microfracture‑plus‑scaffold does not consistently beat microfracture alone on average across RCTs (IKDC/KOOS/VAS/MOCART), so early improvement can look similar in many cohorts.
• Beyond the early window, durability becomes the differentiator: microfracture’s repair tissue and subchondral effects are the main reason many specialists now favour scaffold‑based restoration strategies where feasible, especially for higher‑demand patients and larger focal defects.
• Injectable gels are conceptually aligned with scaffold strategies (matrix support and cell recruitment), but there are not yet robust head‑to‑head randomised trials that let them be “read across” directly from solid scaffold implants.

The main decision shift, therefore, is not that an injectable gel has already proven superiority over microfracture in the knee; it is that focal knee defects are increasingly framed as a scaffold/restoration problem rather than a “drill a few holes” problem. In that framing, an injectable scaffold is most directly competing with debridement and microfracture‑based approaches for contained defects, aiming for symptom and function improvement over the first 1–2 years while trying to preserve better options if further surgery is needed later—whereas joint replacement remains a separate pathway for diffuse, end‑stage disease rather than isolated 1–7 cm² lesions.

Ankle cartilage transplantation versus two stage MACI in the knee

The most useful way to keep “ankle cartilage transplantation” and “next‑generation ACI” claims in proportion is to set a clear benchmark first. To keep the decision points tight (rather than listing every variant), the comparison below uses two‑stage MACI in the knee as the reference standard for cell-based restoration, then shows what has (and has not) translated convincingly to the ankle.

Two‑stage MACI in the knee: the long‑term benchmark

In the knee, MACI is a two‑stage pathway: an initial arthroscopy to take a small cartilage biopsy, laboratory expansion of chondrocytes and seeding onto a collagen membrane, and then a second operation to implant the cell‑seeded matrix into a prepared defect. That two‑step structure matters because it is the main trade‑off for the best-documented durability signal in cartilage restoration.

Long‑term follow‑up is one of MACI’s strongest features in the knee literature. A systematic review with minimum 10‑year follow‑up (168 patients; 188 tibiofemoral defects) reported sustained improvements in patient‑reported outcomes, generally satisfactory defect fill on MRI, a 9.0% all‑cause reoperation rate, and 7.4% progression to total knee arthroplasty over 10–17 years. That kind of horizon is unusual in cartilage repair, and it frames why knee MACI is often treated as a “durability benchmark” rather than simply a symptom‑relief procedure.

Across a broader evidence base, a meta‑analysis covering 47 studies (1,993 patients) found that several reconstructive strategies—ACI/MACI, osteochondral autograft transfer (OAT) and osteochondral allograft (OCA)—each produced significant improvements in knee pain and function scores, with the practical message being that technique choice depends on defect characteristics and patient factors, not that one method is universally best.

When cell-based methods move to the ankle: encouraging, but a shorter runway

In the talus, MACI has been adapted for selected deep osteochondral lesions, and the published outcomes are best read as “promising mid‑term ankle preservation” rather than the decades-long track record seen in knee MACI. A prospective talus MACI series of 22 patients (mean age 23.9 years; mean lesion 1.94 cm²) reported large functional gains with follow‑up to around 63.5 months, and the authors described improvement mainly in the first postoperative year with stability thereafter.

That difference in runway—about 5 years in the talus series versus 10–17 years in knee MACI reviews—helps explain why “ankle cartilage transplantation” can sound more established online than it actually is in published comparative terms. The ankle data are real and clinically useful, but they are not yet a like‑for‑like substitute for the depth of knee MACI follow‑up.

HD‑ACI: an evolution of MACI, not a true single‑stage solution

High‑density ACI (HD‑ACI) is often presented as “next‑generation” because it increases cell seeding density (reported around 5 million chondrocytes/cm² on a membrane) and has produced more hyaline‑like repair cartilage than lower-density approaches in preclinical work. Clinically, HD‑ACI has been used for knee and ankle defects and has been extended to other joints in some reports.

However, the key practical point is that HD‑ACI still relies on ex vivo cell expansion and therefore retains the core MACI trade‑off: it remains a cell-dependent, theatre-based, multi-step pathway, and published clinical outcome data are described as relatively limited compared with the established long-term knee MACI literature.

“Single‑treatment ACI” (STACI): feasible in one operation, but mostly knee-focused and early

True single‑stage ACI-style approaches aim to avoid the two-stage burden by doing harvesting and processing during one operation. A reported single‑surgery co‑implantation technique processed a cartilage biopsy and bone marrow aspirate intraoperatively (around 100 minutes) and implanted a mixed cell population at a standardised dose of roughly 9 million cells/cm², across 141 patients with lesions averaging 4.0 cm².

The centre of gravity of that publication is feasibility—tissue inputs, cell yields, and operating-room logistics—rather than robust, long‑term head‑to‑head outcomes, and the clinical experience described is mainly in the knee rather than the talus. That is why “single‑treatment ACI for the ankle” is still best regarded as emerging: the concept is clear, but ankle‑specific outcome evidence remains thin compared with established two‑stage ankle MACI series.

Where injectable scaffolds (including Liquid Cartilage) fit beside these operative benchmarks

These operative pathways—MACI, HD‑ACI and early STACI-style approaches—share a defining feature: they are cell-based restoration strategies built around surgical defect preparation and the handling of living cells (either expanded in a lab or processed during surgery). Liquid Cartilage / ChondroFiller-type treatments, by contrast, are positioned as a non-cellular, injectable collagen scaffold placed with image guidance as an outpatient treatment, aiming to support the body’s own repair response without a biopsy, laboratory expansion, or a second operation.

That makes injectable scaffolds conceptually closer to a “bridge” in joint preservation—lower treatment burden and no cell-handling pathway—while the cell-based options remain the benchmark when the priority is the most established long-term restorative evidence (currently strongest in the knee MACI literature).

Who hip liquid cartilage might suit instead of early replacement

Painful hip cartilage damage does not always mean a hip replacement is the next step. The common “hip preservation” scenario is a mechanically driven problem—often femoroacetabular impingement (FAI) with a labral tear—where a discrete area of cartilage has failed (a focal full‑thickness defect), but the rest of the joint still has enough cartilage cover that it is not yet behaving like end‑stage arthritis on imaging. In clinical terms this tends to show up in active adults, often with pain provoked by hip flexion and rotation (for example, deep sitting, twisting in sport, or getting in and out of a car).

Where “liquid cartilage” fits in hip preservation

In the peer‑reviewed hip arthroscopy literature, ChondroFiller Liquid is described as a cell‑free collagen matrix used as a one‑step adjunct when a surgeon encounters a symptomatic full‑thickness chondral defect during hip arthroscopy. A 2021 technique report (“needle and curette technique”) sets it firmly in that setting: defect preparation, then delivery of the collagen gel directly into the contained lesion. In the same paper, microfracture is described as the standard approach for small focal hip lesions, but the authors note the usual concern that microfracture produces fibrocartilage, with benefit that can be variable beyond about 2–3 years—one reason biological scaffolds are being explored in the hip.

The key practical implication is that the target is a “pothole”, not a worn‑out road. In the hip, that often means scaffold use alongside other joint‑preserving steps performed in the same operation—most commonly labral repair/reconstruction and correction of the FAI bony mechanics—rather than as a standalone answer to hip pain. Published work in this area is still weighted towards how the material is placed and how to avoid washout from the defect, rather than robust head‑to‑head, long‑term comparisons versus microfracture or arthroplasty.

A “biological plaster”, with limits

Liquid Cartilage’s own hip‑focused material uses the phrase “biological plaster”: the idea is to stabilise a local crack/defect, fill it neatly, and provide a temporary scaffold intended to support repair rather than leaving an exposed defect edge. That framing is consistent with how surgeons describe collagen matrices in focal defect work—supporting the body’s response rather than transplanting living cartilage.

Independent clinician‑education material is also clear about boundaries: ChondroFiller is not a “miracle gel”, is not positioned as a non‑surgical cure for arthritis, and does not “regrow” normal hyaline cartilage across an arthritic joint. It is described as an acellular scaffold for surgically accessed focal defects, with limited published clinical evidence—language that narrows candidacy away from established osteoarthritis and towards contained lesions in otherwise reasonably preserved joints.

Arthroscopy in the literature vs ultrasound guidance in current practice

The hip papers describing ChondroFiller placement are largely arthroscopy‑based, because that is where full‑thickness chondral defects are directly visualised, prepared, and dried before a scaffold is applied. The current LCC service pathway uses the same “scaffold to support a focal defect” concept, but delivers it as an ultrasound‑guided outpatient injection rather than an arthroscopic implant; the intention is still joint preservation in carefully selected focal pathology, not a substitute for mechanical correction when FAI is driving the damage.

How this differs from the usual hip replacement threshold

NHS guidance frames total hip replacement around severe hip pain and disability, most often from arthritis or significant joint damage, where symptoms persist despite conservative measures (for example pain relief, physiotherapy, walking aids) and where daily life and mobility are substantially affected. That “replacement” picture usually corresponds to diffuse cartilage loss and joint‑space narrowing rather than a single contained defect—so it is typically beyond what any focal scaffold approach is designed to address.

In practice, the dividing line is less about a brand name and more about the pattern of disease on MRI/X‑ray: a focal, symptomatic defect in a relatively preserved hip may sit in the joint‑preservation lane (often alongside treatment of FAI/labral pathology), whereas a hip that is globally worn—especially when pain affects sleep and basic walking—more often meets the NHS‑style replacement indications.

Planning your next steps with a cartilage specialist

To keep the emphasis on decision-making rather than promotion, this closing section deliberately avoids clinic-specific sales language and instead distils practical next steps that apply across both NHS and private pathways in 2026.

A sensible plan usually starts with clarifying whether symptoms are being driven by a contained focal defect or by diffuse osteoarthritis—because injectable collagen scaffolds sit in the first category, and the evidence base does not support them as a “miracle” reversal for established arthritis. Independent clinician-facing material is explicit that ChondroFiller-type products are acellular scaffolds with limited published clinical evidence and are not positioned to regenerate normal hyaline cartilage across an arthritic joint.

That distinction depends on a structured assessment built around concrete details: a timeline (for example, symptoms since a 2023 twist injury versus a 5‑year gradual decline), current functional limits (walking distance, stairs, sport), and measurable risk modifiers such as BMI. High-quality imaging is typically central—MRI to characterise cartilage and bone-marrow change, CT where bony architecture matters (often in post-traumatic ankles), and ultrasound when image-guided injection planning is part of the pathway.

A cautious, evidence-led sequencing of options tends to follow a “least irreversible first” logic:

• Optimise symptom management and mechanics (physiotherapy, load management, and—where relevant—alignment and movement strategy).
• For symptomatic focal lesions, consider whether a scaffold-based approach is reasonable as a joint-preservation step, while keeping expectations aligned with the current evidence gaps.
• Escalate to restorative surgery (cartilage transplantation procedures, osteotomy) when lesion pattern and durability goals justify it.
• Reserve fusion or joint replacement for clearly advanced disease; NHS guidance frames hip replacement around severe pain and disability that persist despite conservative measures and substantially affect quality of life and mobility.

In London, specialist joint-preservation assessment is available in several settings; London Cartilage Clinic (Harley Street) sits within the wider MSK Doctors group, allowing decisions to be made with access to both injectable scaffold options and, where appropriate, onward surgical pathways (including cartilage repair and arthroplasty). Earlier escalation to specialist assessment is often helpful when pain is limiting work, sleep, or sport, because the range of joint-preservation options tends to narrow once changes become widespread.

1. [1] Cartilage Defect Treatment Using High-Density Autologous Chondrocyte Implantation (HD-ACI). (2023). https://doi.org/10.3390/bioengineering10091083 https://doi.org/10.3390/bioengineering10091083